American Journal of Obstetrics & Gynecology
Volume 201, Issue 3 , Pages 315.e1-315.e5 , September 2009

Obstetric and newborn infant outcomes in human immunodeficiency virus–infected women who receive highly active antiretroviral therapy

Presented at the 29th Annual Meeting of the Society for Maternal-Fetal Medicine, San Diego, CA, Jan. 26-31, 2009.

  • Sina Haeri, MD, MHSA

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
    • Corresponding Author InformationReprints: Sina Haeri, MD, University of North Carolina School of Medicine, Department of Obstetrics and Gynecology, 3010 Old Clinic Bldg., CB# 7516, Chapel Hill, NC 27599-7516
    • ,
  • Marla Shauer, CNM

      Affiliations

    • Department of Obstetrics and Gynecology, Washington Hospital Center, Washington, DC
    • ,
  • Monica Dale, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Washington Hospital Center, Washington, DC
    • ,
  • Jennie Leslie, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Washington Hospital Center, Washington, DC
    • ,
  • Arthur M. Baker, MD

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
    • ,
  • Stephanie Saddlemire, MSPH

      Affiliations

    • Department of Obstetrics and Gynecology, Washington Hospital Center, Washington, DC
    • ,
  • Kim Boggess, MD

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC

Received 5 February 2009 ,Revised 28 April 2009 ,Accepted 5 June 2009.

References 

  1. Mofenson LM. Technical report: perinatal human immunodeficiency virus testing and prevention of transmission: Committee on Pediatric AIDS. Pediatrics. 2000;106:E88
  2. Centers for Disease Control and Prevention (CDC). Achievements in public health: reduction in perinatal transmission of HIV infection–United States, 1985-2005. MMWR Morb Mortal Wkly Rep. 2006;55:592–597
  3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV. Lancet. 1998;352:1725–1730
  4. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/ContentFilesAccessed Feb. 5, 2009
  5. Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet. 2002;360:1152–1154
  6. Suy A, Martínez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS. 2006;20:59–66
  7. Dube MP, Sattler FR. Metabolic complications of antiretroviral therapies. AIDS Clin Care. 1998;10:41–44
  8. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. BJOG. 1998;105:836–848
  9. Leroy V, Ladner J, Nyiraziraje M, et al. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992-1994. AIDS. 1998;12:643–650
  10. Ross MG, Beall MH. Adult sequelae of intrauterine growth restriction. Semin Perinatol. 2008;32:213–218
  11. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. BJOG. 1998;105:836–848
  12. Martin R, Boyer P, Hammill H, et al. Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers: the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Infection study group. J Pediatr. 1997;131:851–856
  13. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects: Swiss HIV Cohort study, the Swiss Collaborative HIV and Pregnancy study, and the Swiss Neonatal HIV study. AIDS. 1998;12:F241–F247
  14. European Collaborative Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14:2913–2920
  15. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863–1870
  16. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449–473
  17. Tuomala RE, Yawetz S. Protease inhibitor use during pregnancy: is there an obstetrical risk?. J Infect Dis. 2006;193:1191–1194
  18. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21:607–615

 Supported by the MedStar Research Institute and a Washington Hospital Center Graduate Medical Education Research Grant.

 Cite this article as: Haeri S, Shauer M, Dale M, et al. Obstetric and newborn infant outcomes in human immunodeficiency virus–infected women who receive highly active antiretroviral therapy. Am J Obstet Gynecol 2009;201:315.e1-5.

PII: S0002-9378(09)00639-5

doi: 10.1016/j.ajog.2009.06.017

American Journal of Obstetrics & Gynecology
Volume 201, Issue 3 , Pages 315.e1-315.e5 , September 2009

Article Tools